{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:00:32Z","timestamp":1793523632610,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.critrevonc.2013.07.011","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:45:43Z","timestamp":1376354743000},"page":"655-666","source":"Crossref","is-referenced-by-count":41,"title":["Targeting inflammatory pathways in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"88","author":[{"given":"Uri","family":"Rozovski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2013.07.011_bib0005","series-title":"UpToDate","article-title":"Staging and prognosis of chronic lymphcoytie leukemia","author":"Rai","year":"2013"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0010","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.1987.tb02333.x","article-title":"Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases","volume":"67","author":"Duhrsen","year":"1987","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V26.3.257.257","article-title":"Exaggerated Delayed Hypersensitivity to Mosquito Bites in Chronic Lymphocytic Leukemia","volume":"26","author":"Weed","year":"1965","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0190-9622(98)70398-6","article-title":"Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients","volume":"39","author":"Davis","year":"1998","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4065\/75.10.1039","article-title":"Infection and immunity in chronic lymphocytic leukemia","volume":"75","author":"Tsiodras","year":"2000","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","author":"Dearden","year":"2008","journal-title":"American Society of Hematology Education Program"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/172460089300800103","article-title":"Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia","volume":"8","author":"Pavlidis","year":"1993","journal-title":"International Journal of Biological Markers"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0045","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2008.18.1701","article-title":"Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment","volume":"27","author":"Wierda","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1471-4906(03)00076-0","article-title":"Beta2-microglobulin as a potential initiator of inflammatory responses","volume":"24","author":"Xie","year":"2003","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0055","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","article-title":"Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia","volume":"118","author":"Yan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0060","doi-asserted-by":"crossref","first-page":"453634","DOI":"10.4061\/2009\/453634","article-title":"Gene expression and serum cytokine profiling of low stage CLL identify WNT\/PCP, Flt-3L\/Flt-3 and CXCL9\/CXCR3 as regulators of cell proliferation, survival and migration","volume":"2009","author":"Mahadevan","year":"2009","journal-title":"Human Genomics and Proteomics"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0065","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V97.1.256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0070","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2012.666662","article-title":"Association of interleukin-6 and interleukin-8 with poor prognosis in elderly chronic lymphocytic leukemia patients","author":"Yoon","year":"2012","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.1989.tb04290.x","article-title":"Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro","volume":"71","author":"Collins","year":"1989","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0080","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.humpath.2011.02.027","article-title":"Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3","volume":"42","author":"Badoux","year":"2011","journal-title":"Human Pathology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","article-title":"Nurture versus nature: the microenvironment in chronic lymphocytic leukemia","volume":"2011","author":"Burger","year":"2011","journal-title":"Hematology American Society of Hematology Education Program"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/1078-0432.CCR-11-1049","article-title":"Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells","volume":"18","author":"Dietrich","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0095","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood.V89.3.941","article-title":"Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta","volume":"89","author":"Douglas","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2003-02-0540","article-title":"Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway","volume":"103","author":"Kern","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0105","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2008-12-196568","article-title":"Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases","volume":"114","author":"Del Giudice","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2008.07070.x","article-title":"Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia","volume":"141","author":"Palmer","year":"2008","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0115","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3109\/10428194.2010.503820","article-title":"Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia","volume":"51","author":"Gonzalez-Rodriguez","year":"2010","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0120","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0125","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1182\/blood.V91.11.4273","article-title":"Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1\/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia","volume":"91","author":"Tinhofer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0130","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nm0997-984","article-title":"Acquired CD40-ligand deficiency in chronic lymphocytic leukemia","volume":"3","author":"Cantwell","year":"1997","journal-title":"Nature Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0135","first-page":"494","article-title":"Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia","volume":"10","author":"Rossi","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0140","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0145","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nri2853","article-title":"The tipping points in the initiation of B cell signalling: how small changes make big differences","volume":"10","author":"Pierce","year":"2010","journal-title":"Nature Reviews Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0165","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1126\/science.1071546","article-title":"B cell antigen receptor signaling: roles in cell development and disease","volume":"296","author":"Gauld","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0170","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1146\/annurev.immunol.21.120601.141018","article-title":"B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor","volume":"21","author":"Chiorazzi","year":"2003","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0175","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","article-title":"Chronic lymphocytic leukemia: revelations from the B-cell receptor","volume":"103","author":"Stevenson","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0180","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1172\/JCI19399","article-title":"Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia","volume":"113","author":"Ghiotto","year":"2004","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0190","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood-2004-03-0818","article-title":"Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins","volume":"104","author":"Widhopf","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0195","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0200","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/ni.1666","article-title":"Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling","volume":"9","author":"Stadanlick","year":"2008","journal-title":"Nature Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0205","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1172\/JCI119869","article-title":"B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues","volume":"100","author":"Frank","year":"1997","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1541-7786.MCR-10-0559","article-title":"STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells","volume":"9","author":"Liu","year":"2011","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nature Genetics"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0220","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0230","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.it.2006.09.002","article-title":"Innate immune recognition of, and regulation by, DNA","volume":"27","author":"Ishii","year":"2006","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0235","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.1183021","article-title":"Regulation of adaptive immunity by the innate immune system","volume":"327","author":"Iwasaki","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0240","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2011-10-386144","article-title":"NOTCH1 mutations in CLL associated with trisomy 12","volume":"119","author":"Balatti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1471-4914(02)00003-5","article-title":"Notch, a unifying target in T-cell acute lymphoblastic leukemia?","volume":"9","author":"Screpanti","year":"2003","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0250","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/85798","article-title":"DNA double-strand breaks: signaling, repair and the cancer connection","volume":"27","author":"Khanna","year":"2001","journal-title":"Nature Genetics"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0255","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0260","first-page":"2003","article-title":"Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease","volume":"9","author":"Fegan","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0265","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2011.049270","article-title":"ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression","volume":"97","author":"Guarini","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0275","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/1097-0142(196904)23:4<900::AID-CNCR2820230427>3.0.CO;2-4","article-title":"Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia","volume":"23","author":"Ezdinli","year":"1969","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0280","first-page":"1681","article-title":"Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies","volume":"8","author":"Greenstein","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0285","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.2830470421","article-title":"High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia patients","volume":"47","author":"Molica","year":"1994","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0290","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","article-title":"High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities","volume":"82","author":"Thornton","year":"2003","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0295","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V92.4.1406","article-title":"Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells","volume":"92","author":"Bellosillo","year":"1998","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0300","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clim.2005.12.012","article-title":"Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells","volume":"120","author":"Ryan","year":"2006","journal-title":"Clinical Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0305","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00262-007-0374-4","article-title":"Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells","volume":"57","author":"Ryan","year":"2008","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0310","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3109\/10428194.2010.486877","article-title":"Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia","volume":"51","author":"Shanafelt","year":"2010","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0315","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1080\/10428190600948147","article-title":"Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells","volume":"47","author":"Robak","year":"2006","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0320","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00280-006-0400-9","article-title":"R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells","volume":"60","author":"Lindhagen","year":"2007","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0325","series-title":"Concurrent use of aspirin with the fludarabine, cyclophophamide, rituximab (fcr) regimen improves outcome in patients with relapsed\/refractory CLL","author":"Young Kwang Chae","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0330","first-page":"975","article-title":"Statins and endothelial dysfunction","volume":"113","author":"Filip-Ciubotaru","year":"2009","journal-title":"Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0335","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-2004-869590","article-title":"Statins and endothelial dysfunction","volume":"4","author":"Larose","year":"2004","journal-title":"Seminars in Vascular Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0340","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0165-6147(02)02077-1","article-title":"Statins as anti-inflammatory agents","volume":"23","author":"Weitz-Schmidt","year":"2002","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0345","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0350","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1172\/JCI1500","article-title":"Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells","volume":"101","author":"Hernandez-Perera","year":"1998","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0355","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/hq0202.104081","article-title":"Cellular antioxidant effects of atorvastatin in vitro and in vivo","volume":"22","author":"Wassmann","year":"2002","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0360","doi-asserted-by":"crossref","first-page":"F53","DOI":"10.1152\/ajprenal.00041.2008","article-title":"Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability","volume":"295","author":"Zhou","year":"2008","journal-title":"Renal Physiology. American Journal of Physiology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0365","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0301-472X(03)00192-9","article-title":"Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9","volume":"31","author":"Chapman-Shimshoni","year":"2003","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0370","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2567.2006.02505.x","article-title":"Statins inhibit lymphocyte homing to peripheral lymph nodes","volume":"120","author":"Schramm","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0375","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/eji.200838278","article-title":"Simvastatin impairs humoral and cell-mediated immunity in mice by inhibiting lymphocyte homing, T-cell activation and antigen cross-presentation","volume":"38","author":"Ulivieri","year":"2008","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0380","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pmed.0050064","article-title":"Statins impair antitumor effects of rituximab by inducing conformational changes of CD20","volume":"5","author":"Winiarska","year":"2008","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0385","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3109\/10428194.2010.520050","article-title":"Statin use and need for therapy in chronic lymphocytic leukemia","volume":"51","author":"Friedman","year":"2010","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0390","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0395","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0400","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Amrein","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0405","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1182\/blood-2011-07-369041","article-title":"Dasatinib inhibits proinflammatory functions of mature human neutrophils","volume":"119","author":"Futosi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0410","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"363","author":"Weinblatt","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0415","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0420","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0425","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1158\/1078-0432.CCR-11-1402","article-title":"Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia","volume":"18","author":"Herman","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0430","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia","author":"Byrd","year":"2013","journal-title":"England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0435","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0440","author":"Byrd","year":"2012"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0445","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0450","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0455","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0460","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/107327481201900106","article-title":"Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia","volume":"19","author":"Carballido","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0465","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0470","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0475","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0480","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0485","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0490","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0495","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0500","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0505","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0510","first-page":"451","article-title":"Inflammation in aging: cause, effect, or both?","volume":"13","author":"Jenny","year":"2012","journal-title":"Discovery Medicine"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0515","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/0126839-200809060-00005","article-title":"New approaches to the treatment of inflammatory disease: focus on small-molecule inhibitors of signal transduction pathways","volume":"9","author":"Ivanenkov","year":"2008","journal-title":"Drugs in R&D"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0520","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2010.10.004","article-title":"Treating inflammation with the Janus kinase inhibitor CP-690,550","volume":"32","author":"Vijayakrishnan","year":"2011","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0525","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/10428190400018398","article-title":"Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia","volume":"46","author":"Martinez-Lostao","year":"2005","journal-title":"Leukemia and Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.07.011_bib0530","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.55.55","article-title":"CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 delta, Demonstrates Clinical Activity and Pharmacodynamic Effects In patients with Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"116","author":"Furman","year":"2010","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T20:48:04Z","timestamp":1688417284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1040842813001625"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}